Thursday, December 26, 2019 10:19:31 AM
Clearly an inflection point here however IMO ..... MGMT MUST EXECUTE NOW.
Dahl has already put out there the desire for large capital campaign. Given the recent news, the likely appropriate course of action is an immediate capital raise to finish up outstanding items that will produce revenue the fastest. Whether that revenue is commercial, license, option payments. It's clear that SOME CASH is needed, but NOT a giant raise.
IMO, if Dahl has fish on the hook, which I think he does, I think the best course is an LOC type deal where financier will provide money up to say $5-$8 million at ZIVOs discretion and at prevailing market prices at the time drawn. Minimum $500k per draw. Initial draw ... Whatever it takes to produce revenue the fastest. Recent news IMO puts ZIVO in much stronger position and as a result should be able to get money on better terms.
Have seen this type deal many times. Gives ZIVO flex to react IMMEDIATELY TO SUPPORT ACTIVITIES CONDUCIVE TO PRODUCING REVENUE THE FASTEST while limiting the dilutive effect to the capital structure.
I would anticipate a financing deal of this nature would be most advantageous and quite frankly give Dahl a chance to shine.
Within 6 months, commercial scale algae production, poultry GRAS and commercial sales via Nutriquest, option payments from Zoetis, license deal with a top 10 pharma, sales to nutraceutical market for human application, Grekin, Chipuras, would like to see Royal DSM link up with the algae instead of Wellmetrix, there are endless possibilities ......
This course should limit the need to draw against LOC deal assuming that revenues may be generated from licensing/development deals and Nutriquest in particular.
As this plays out, as I said, the valuation metrics change from basically being a bad joke for almost 2 decades, to those of a legitimate biotech with novel molecular candidate with potential target markets into multi billions each.
Inflammation and immune response ...
Pharma - multiple human and animal (Zoetis) candidates
Ingredients - multiple human and animal applications (Nutriquest), nutraceutical, food, beverage (health and sports drinks) and cosmetics (Grekin)
Nutraceutical - how about the glucosamine (joint health supplement) fantasy debunked and replaced by supplement provided by ZIVO eh ?????
How about a new class of sports drinks ??? Move over Gatorade !!!
Cosmetics/sunscreens/topical analgesics ?
The list can go on and on.
I did valuation metrics on ZIVO in the past based on the expectation of being able to isolate the molecule and sell into multiple verticals. I don't recall that I publicly ever offered those numbers mainly because I did not believe Dahl could do it, and the numbers would likely get quite the laugh. The number is Big. Still don't think Dahl can handle it though.
Food for thought ..... pun intended =)
Amigo Mike
Recent ZIVO News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/26/2024 05:36:56 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/26/2024 12:05:12 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 04/09/2024 03:49:14 PM
- Form SCHEDULE 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 03/14/2024 01:16:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:45:37 PM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 02/15/2024 01:54:37 PM
- ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study • Business Wire • 02/07/2024 09:54:00 PM
- ZIVO Bioscience Announces Uplisting to OTCQB Market • Business Wire • 01/29/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:11:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 10:17:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:05:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 10:23:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:12:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 02:29:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 09:21:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:18:41 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 10/30/2023 05:20:31 PM
- ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens • Business Wire • 10/30/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 12:56:59 PM
- ZIVO Bioscience Announces Reverse Stock Split • Business Wire • 10/26/2023 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 10/04/2023 09:08:51 PM
- ZIVO Bioscience to Present at the Dawson James Small Cap Growth Conference • GlobeNewswire Inc. • 10/03/2023 12:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM